Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
NCT03838692Phase 2Withdrawn
- Start
- Jul 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ponatinib in Medullary Thyroid Cancer (MTC). Planned start Jul 2019; status: withdrawn.
02
Drugs
ponatinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT03838692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838692.